Educational information only — not a diagnosis or treatment recommendation.
Content last checked: Jul 15, 2026·Sources & review
You do not need to choose surgery or radiation on day one. First clarify risk group, then decide whether monitoring or treatment fits — and only then compare surgery versus radiation. Start from the decision you are facing now.
Your decision map · about 3 minutes
A diagnosis creates many questions at once. You do not need to solve them all today. This is a navigation map, not a reading list — find the decision you are facing now, open one guide, then return when the next question comes up.
Quick start
Jump to a situation below — same map, fewer steps to choose.
Optional foundation
You can start with a decision situation below even if you do not know all the details yet. Open a short guide only if you want basics first.
First clarify risk group (PSA, Grade Group / Gleason, MRI) and what is still pending — before locking monitoring or treatment.
You may also need to consider
Is active surveillance a reasonable option for me?Active surveillance is often the first prostate-specific fork. If definitive therapy is recommended, compare surgery and radiation next.
You may also need to consider
Should I get a second opinion before deciding?Urinary, sexual, and bowel tradeoffs — plus cost, time, and whether a plan is workable day to day.
When you want another review, more confidence, or specialists frame the same options differently.
You may also need to consider
When should I consider prostate cancer care abroad?When monitoring or post-treatment PSA changes and you need the next decision frame.
You may also need to consider
Should I get a second opinion before deciding?Monitoring plans, triggers for change, and life after treatment.
You may also need to consider
Is active surveillance a reasonable option for me?For search and first visits
Short answers that point to one decision guide — not a full reading list.
You usually do not need to choose surgery or radiation today. First clarify risk group (PSA, Grade Group / Gleason, MRI) and what results are still pending — then ask whether monitoring could be reasonable.
First steps after diagnosis →Not always. For selected lower-risk cancers, active surveillance can defer treatment side effects while watching for change. Ask what features make surveillance appropriate — and what would end it.
Active surveillance guide →When definitive therapy is recommended, both can be reasonable. Compare cancer-control expectations and urinary, sexual, and bowel tradeoffs for your priorities — not a single “best” treatment for everyone.
Surgery vs radiation →Urology and radiation oncology often frame the same options differently. Ask where they disagree, what would change each recommendation, and whether a joint consult or second opinion helps.
Second opinion guide →Often yes, when pending imaging, pathology review, or specialist input could change whether surveillance or treatment fits. Ask what is safe to wait for — and what must happen this week.
What can wait →Prostate cancer decisions often follow risk clarity → active surveillance versus treatment → surgery or radiation. This center is a situation-based Decision Journey so patients can leave with a clear next step — not an encyclopedia. Full Entry guides deepen next; the map is live now.
Understanding prostate cancer risk group
Orient to PSA, Grade Group / Gleason, and MRI — why risk shapes monitoring versus treatment, not a prognosis table.
Open Understanding Risk Group →Understanding prostate cancer stage
Orient to localized, locally advanced, and metastatic extent — why stage changes options, not a prognosis table.
Open Understanding Stage →Treatment Landscape
Orient to surveillance, surgery, radiation, and hormone therapy — so later comparisons make sense.
Open Treatment Landscape →Cross-border care is a branch of the journey when a specific capability is missing locally — not a default destination.
Editorial examples of how patients compare options — not verified personal testimonials.
Complete node graph for structure and deep links — most people can stay with the situation map and nearby decisions above.
Diagnosis confirmed
Confirm what is known — PSA, Grade Group / Gleason, MRI and staging — and which decisions are time-sensitive versus deliberately paced.
Why this matters: Early prostate decisions depend on risk clarity. Rushing treatment before risk is clear can close off surveillance when it would have been reasonable.
Decision questions
Illustrative journey
Decision fork — paths can run in parallel
Monitor or treat
Decide whether structured monitoring is reasonable for your risk group — or whether definitive therapy is favored now.
Why this matters: This is the prostate-distinctive fork: for selected lower-risk cancers, surveillance can defer treatment side effects while watching for change.
Decision questions
Illustrative journey
Treatment comparison
Compare surgery and radiation (and related options) when definitive therapy is on the table — including side-effect tradeoffs that matter to you.
Why this matters: Multiple guideline-supported paths can be reasonable. The useful comparison is fit for your risk group and priorities, not a single “best” treatment.
Decision questions
Another review
Decide whether another expert review helps before locking surveillance or definitive therapy.
Why this matters: Prostate pathways often diverge across specialties. An independent review can confirm risk group and clarify fit with your priorities.
Decision questions
Urology vs radiation framing
When urology and radiation oncology frame options differently, clarify where they disagree and what would reconcile the plan.
Why this matters: Specialty differences are often complementary perspectives — not proof that one doctor is wrong.
Decision questions
Cost and logistics
Compare how surveillance, surgery, and radiation concentrate costs and time — including follow-up and complications.
Why this matters: Cost and logistics belong in the decision when pathways are otherwise similar for your risk group.
Decision questions
Branches to
International option
Only explore cross-border care when a specific capability or high-volume expertise is missing locally.
Why this matters: Abroad care matters only when a capability gap is real — not as a default upgrade.
Decision questions